1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If the results demonstrate a positive safety and efficacy profile, this study could pave the way for a novel adjunctive treatment strategy for a particularly challenging patient population. Adults with Type 1 Diabetes…
Establishing bioequivalence is crucial for pharmaceutical products, especially when manufacturing processes are altered, as it confirms that the drug's performance remains consistent. This finding means that patients …
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
This study provides compelling evidence that PPARγ and GLP1 receptor agonists can directly improve brain metabolism and neuronal mitochondrial function, offering a novel therapeutic avenue for cognitive health. The us…
This research underscores the significant potential of microalgae as a sustainable and scalable bioreactor for producing novel therapeutic peptides with antidiabetic properties. The identification of potent hypoglycae…
This study provides crucial insights for plastic surgeons and patients, indicating that GLP-1 RA-induced weight loss may be associated with a slightly lower incidence of minor complications following body contouring s…
This comprehensive analysis provides crucial evidence for clinicians and patients in selecting the most effective GLP-1 receptor mono-agonist formulation for cardiometabolic improvement. The findings highlight the sup…
This study provides strong evidence that GLP-1 Receptor Agonists, exemplified by semaglutide, can directly improve cardiac function and clinical outcomes in patients with HFrEF, beyond their established metabolic bene…
This systematic review underscores the transformative potential of GLP-1 receptor agonists in the management of obesity and its associated health complications. The consistent and significant weight loss observed, cou…
This review highlights the significant potential of GLP-1 RAs as a novel adjunctive therapy for Cystic Fibrosis, offering benefits beyond their established role in diabetes management. Their pleiotropic effects could …
This research highlights that tirzepatide offers substantial cardiovascular benefits, specifically in reducing blood pressure and improving heart function, independent of its known metabolic effects. The observed modu…
This research highlights a potentially significant benefit of GLP-1 receptor agonists in a high-risk population with advanced heart failure. While primarily known for managing diabetes and obesity, these findings sugg…
This "complex clinical encounter series" brings to the forefront a crucial, yet often underappreciated, aspect of GLP-1 RA therapy: its potential long-term impact on bone health. The key implication is that current cl…
This study holds significant promise for improving the lives of individuals with Type 1 Diabetes. If successful, the combination of a GLP-1 receptor agonist and an SGLT2 inhibitor with AID could offer a novel and high…
The identification of genetic predictors for GLP-1 response holds significant implications for personalized medicine in managing prediabetes, type 2 diabetes, and obesity. This research could lead to tailored therapeu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…
This real-world evidence confirms the effectiveness and safety of oral semaglutide in a diverse Mexican adult population, closely mirroring the positive outcomes observed in more controlled clinical trials. The signif…
This review underscores the increasing importance of real-world evidence (RWE) in shaping healthcare decisions, from reimbursement to regulatory approval. By demonstrating how RWE is being effectively utilized and ide…
This comprehensive network meta-analysis provides crucial evidence for guiding treatment decisions in a high-risk patient population. The findings strongly support the preferential use of SGLT2 inhibitors and GLP-1 re…
This study provides crucial mechanistic insights, demonstrating that semaglutide exerts direct hepatoprotective actions via GLP-1 receptors on intrahepatic sinusoidal endothelial cells, independent of its weight-reduc…
This research is highly significant as it identifies semaglutide as a promising novel candidate for treating cocaine use disorder. Given the severe lack of effective pharmacological interventions for addiction, these …
This commentary underscores the urgent need for a proactive public health strategy to manage the societal implications of GLP-1RA proliferation. The authors argue that without clear guidelines and public education, th…
This study provides compelling evidence that Tirzepatide offers substantial cardiovascular protection beyond its established glucose-lowering and weight-loss benefits, positioning it as a critical therapy for patients…
This study provides compelling evidence that tirzepatide, a dual GLP-1 and GIP receptor agonist, offers substantial cardiovascular protection beyond its established glycemic control and weight loss benefits in patient…
This study provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly improves cardiovascular outcomes in patients with Type 2 Diabetes and high cardiovascular risk. This posit…
This study provides compelling evidence that tirzepatide offers significant and broad cardiovascular protection beyond its established glycemic and weight-loss benefits, positioning it as a leading therapy for Type 2 …
This landmark study provides compelling evidence that Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, offers substantial cardiovascular prot…
These findings are profoundly significant, as they establish Tirzepatide as a potent agent for cardiovascular risk reduction in patients with Type 2 Diabetes and existing cardiovascular disease, moving beyond its know…
This comprehensive real-world analysis provides crucial insights into the differential cardiovascular benefits of two cornerstone drug classes for Type 2 Diabetes. The findings highlight that GLP-1 RAs may be more eff…
The findings from SURPASS-CVOT establish tirzepatide as a potent therapeutic agent for reducing cardiovascular risk in patients with type 2 diabetes, offering benefits beyond its metabolic effects. This is particularl…
GLP-1 RAs represent a highly promising pharmacological approach for managing prediabetes and actively preventing its progression to type 2 diabetes. Their dual action on glucose control and weight loss addresses key p…
The widespread use of GLP-1 RAs for managing diabetes and obesity makes understanding their perioperative implications critically important for patient safety. This study directly addresses the potential for increased…
This research is crucial because it addresses a significant unmet need for effective and safe treatments for obesity and cardiovascular risk in individuals with Type 1 Diabetes. If Semaglutide proves effective in impr…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
This Phase 1 study is a critical foundational step for advancing NNC0480-0389 as a potential combination therapy. If the drugs can be safely co-administered without adverse pharmacokinetic interactions, it significant…
This study is crucial because it seeks to uncover a novel mechanism by which semaglutide promotes weight loss, specifically through its impact on brown adipose tissue (BAT). Understanding this pathway could lead to mo…
This study holds significant promise for overweight and obese women struggling with infertility, potentially offering a novel therapeutic strategy to improve IVF success rates. If Semaglutide pre-treatment proves effe…